businesspress24.com - Atossa Genetics to Announce Third Quarter 2013 Results on Tuesday, November 12, 2013
 

Atossa Genetics to Announce Third Quarter 2013 Results on Tuesday, November 12, 2013

ID: 1281138

(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 11/08/13 -- (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate developments for the quarter ended September 30, 2013, following the close of market on Tuesday, November 12, 2013.

Management will host a conference call on Tuesday, November 12, 2013, at 4:45 pm Eastern Time to review financial results and corporate highlights. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 866-652-5200. International callers should call 412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at .

A replay of the call will be available approximately one hour after the end of the call through December 12, 2013. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID number is 10036358.



Atossa Genetics, Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc., laboratory services and tests. For additional information, please visit .



Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902


MBS Value Partners
Matthew D. Haines (Investors)
Managing Director
(O) 212-710-9686




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2013 Financial Results
Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies
Bereitgestellt von Benutzer: Marketwired
Datum: 08.11.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 1281138
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SEATTLE, WA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 118 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Announce Third Quarter 2013 Results on Tuesday, November 12, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von

Atossa Genetics Inc (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Atossa Genetics Inc



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 124


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.